| PRIMARY INFORMATION |
|---|
| ID | 1239 |
| PMID | 11179600 |
| Year | 2001 |
| Sequence | pGlu-3-methyl-HP |
| Name | M-TRH |
| Length | 3 |
| N-Terminal Modification | Free |
| C-Terminal Modification | Amidation |
| Linear/ Cyclic | Linear |
| Chirality | L |
| Chemical Modification | pGlu= Pyroglutamic acid, 3-methyl-H=3-methyl-histidine |
| Origin of Peptide | Analogue of TRH |
| Nature of Peptide/Cargo | TRH has potential clinical value in the treatment of neurotrauma and various neurologic and psychiatric disorders besides its well known endocrinological effects |
| Mechanism | Not mentioned |
| Cargo Sequence/Structure | None |
Name of cargo
| Not applicable |
| Assay | Cardiovascular parameters and blood gas values determined by collecting blood at different time intervals |
| Enhancer | None |
| Properties of enhancer | Not applicable |
| Concentration | Initially 100µl of 5 mg/ml of peptide was applied followed by continuous renewal by 50µl/h. |
| Incubation time | 60 Minutes |
| Tissue permeability (value with units) | On application of M-TRH, cardiovascular parameters and blood gas values:Mean arterial blood pressure(kPa)-10.1 ± 0.5, Basal skin blood flow(PU)-259 ± 69, Heart rate(min-1)-378 ± 4, Respiratory rate(min-1)-110 ± 8, pH-7.41 ± 0.01, pCO2(pKa)-6.51 ± 0.04 and pO2(pKa)-8.44 ± 0.46 |
| Tissue Sample | Stratum corneum of the abdominal area of male Sprague-Dawley rats |
| Ex vivo/In vivo/In vitro | in vivo |
| SECONDARY INFORMATION |
|---|
| STRUCTURE | |
| SMILES | N.A. |
